Effects of Semax on Dopaminergic and Serotoninergic Systems of the Brain

  title={Effects of Semax on Dopaminergic and Serotoninergic Systems of the Brain},
  author={K. O. Eremin and V. S. Kudrin and Igor A. Grivennikov and N F Miasoedov and Kirill S. Rayevsky},
  journal={Doklady Biological Sciences},
Short-term effects of the synthetic nootropic peptide Semax on the content and metabolism of monoamines in the brain of C57/Bl 6 mice and Sprague–Dawley rats were studied. [] Key Result Intraperitoneal injection of Semax at a dose of 0.15 mg/kg caused an increase in the tissue concentrations of 5-hydroxyindoleacetic acid (5-HIAA) in the hypothalamus and striatum of mice 0.5 and 2 h after the injection.
Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism
It was showed that both peptides did not affect motor activity of rats in elevated cross shaped maze and passive defensive behavior of the animals and toxic damage of substantia nigra does not affect the response of the rat organism on this peptide.
Study of the relationship between analgesic activity and structure of synthetic melanocortin analogs
The peptide analgesic effect was observed after the replacement of the N-terminal methionine with lysine or after the attachment of glucuronic acid to the methions, while the peptide with glycine instead of the methionines had no effect on pain sensitivity.
Peptide ACTH4-7-PGP: Effects on Various Types of Pain and Pain-Induced Behavior in Rats after Systemic and Central Administration.
It was found that the peptide increased pain sensitivity and induced avoidance behavior during thermal stimulation ("hot plate" test), but had an analgesic effect (more pronounced after central administration) and weakened emotional-affective behavior in electrocutaneous stimulation of the paws and tail in rats.
Semax prevents functional impairments of avoidance response in rats
The effects of Semax is studied on the development of avoidance conditioning in rats and its functional impairments modeled using failure and spatialmodification approaches.
Therapeutic Possibility of “Semax” for Depression
  • C. Pae
  • Psychology, Biology
    CNS Spectrums
  • 2008
The therapeutic possibility of a revolutionary neuropeptide, "Semax" functioning as neuroregulator, neuromodulator and neuroprotector, in relation with the treatment of major depression is suggested, indicating its potential effectiveness for elderly depressed patients who are frequently accompanied with comorbid neurological conditions.
Differently Directed Influences of Semax on the Formation and Functional Impairments of an Active Avoidance Reaction in Rats
Data support the view that this peptide has nootropic properties and stimulated reproduction of the avoidance reaction in the shuttle box in rats after functional impairment induced by acute changes in cause-effect and spatial relationships in the experimental environment.
The Potency of Semax Peptide Therapy toward MDA Level and Protein Profile in Epilepsy Rats (Rattus norvegicus)
50 μg/kg body weight dose of semax peptide can be used for the treatment of epilepsy because it is a neuropeptide that directly acts on the central nervous system and free from hormonal activity, therefore it will not cause negative health effects.
A New Generation of Drugs: Synthetic Peptides Based on Natural Regulatory Peptides
The results of research aimed at studying the influence of these peptides on the transcriptome of brain cells are presented, which were the bases for the creation of new drugs that are used effectively in the treatment of various diseases of the nervous system.
Semax as a Universal Drug for Therapy and Research
The rationale for the long-term therapeutic effects of this peptide drug is presented and a comparative analysis of the temporal dynamics of the expression of certain genes is carried out.


Melanocortins and the brain: from effects via receptors to drug targets.
SUMMARY Nootropic properties of ACTH4-10 analogue, Semax, were demonstrated in experiments with human volunteers. The antihypoxic effect of Semax was shown by EEG analysis after shortterm
Anxiolytic-Like and Antidepressant-Like Activities of MCL0129 (1-[(S)-2-(4-Fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a Novel and Potent Nonpeptide Antagonist of the Melanocortin-4 Receptor
Observations indicate that MCL0129 is a potent and selective MC4 antagonist with anxiolytic- and antidepressant-like activities in various rodent models.
  • Zh. Vyssh. Nervn. Deyat
  • 1997